Navigation Links
Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures
Date:7/23/2014

BRUSSELS, July 23, 2014 /PRNewswire/ -- regulated information -- UCB today announced an important advance in its research and development pipeline with positive topline results from the latest Phase 3 study with brivaracetam. This study was designed to evaluate the efficacy and safety of brivaracetam (100 and 200 mg/day, without titration) compared to placebo, as adjunctive treatment in adult focal epilepsy patients with partial-onset seizures, not fully controlled despite treatment with one or two concomitant antiepileptic drugs (AEDs).2

Results showed that brivaracetam reduced partial-onset seizure frequency and improved responder rates, both with statistical significance. The most commonly reported adverse events were somnolence, dizziness, fatigue and headache.3

"Today's positive results with brivaracetam represent a significant milestone in our strategy to deliver new treatment options for people with severe diseases. As the newest product to emerge from our late-stage pipeline, brivaracetam is leading the way for UCB's new era of patient-centric solutions," said Jean-Christophe Tellier, CEO-Elect, UCB. "We are proud to provide AED options for the epilepsy community today, and remain committed to addressing the unmet needs of adult patients who continue to experience uncontrolled seizures."

"The positive data from the most recent Phase 3 study demonstrated robust and clinically relevant seizure reduction in predominantly treatment resistant patients, and tolerability was consistent with previous brivaracetam trials,"4-6 said Professor Dr. Iris Loew Friedrich, Chief Medical Officer and Executive Vice President, UCB.  "This study was the largest Phase 3 study conducted in epilepsy patients with partial-onset seizures. Overall, the brivaracetam developmen
'/>"/>

SOURCE UCB
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Majority of Biotech/Pharma Employees Poised to Job Hunt
2. ZenCash Plucks Top Executives from Major DFW Brands
3. Accelerated Cure Project for Multiple Sclerosis Approved for Major Funding Award from Patient-Centered Outcomes Research Institute to Create MS Patient-Powered Research Network
4. Clinovo Rolls Out Major Enhancements for Open Source EDC ClinCapture at Outsourcing in Clinical Trials West Coast Conference
5. Verified Clinical Trials Stops Dual Enrollment in Clinical Trials in Major CNS Clinical Trials to Reduce Potential Adverse Events and Improve Data Quality
6. Major CRO Gives Top Ratings To Verified Clinical Trials To Stop Dual Enrollment In Clinical Trials On Late Phase Trial
7. Kibow Biotech Achieves Major Victory with Indias IPAB Decision to Uphold 2009 Product Patent
8. Sales Momentum Introduces 5 Payoffs to Asking Questions in Sales Calls in a White Paper - Mastering Major Account Selling
9. Dyadic International To Present At Two Major Conferences In December 2013
10. Sales Momentum Shares Three Common Pitfalls to Avoid When Developing Major Account Sales Strategies
11. The Blazing Diamond and the Quantum Jewel: Two Major Discoveries in Quick Succession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... BILLERICA, Mass. , July 28, 2015 /PRNewswire/ ... for measuring cell metabolism, is the provider of ... utilized across all disease research areas. As the ... revealed, exploration into cell metabolism is escalating rapidly.   ... been published by the Nature Publishing Group (NPG) ...
(Date:7/28/2015)... 28, 2015 Deerfield Management Company, L.P. today ... L.P., which will invest in groundbreaking advancements in science ... cancer, and orphan diseases. The venture capital fund will ... are developed and improve the way healthcare is delivered ... largest healthcare-focused venture funds in the sector, will donate ...
(Date:7/28/2015)... OF PRUSSIA, Pa. , July 28, 2015 /PRNewswire/ ... U.S. Food and Drug Administration has accepted for review ... investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment ... met all primary endpoints. Hemophilia ... deficient or defective factor VIII; nearly all affected patients ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: AMGN ... quarter financial results on Thursday, July 30, 2015, after ... will be followed by a conference call with the ... call from Amgen will be Robert A. Bradway ... of Amgen,s senior management team. Live audio ...
Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, ... JP Morgan,s 30th Annual Healthcare Conference, being held January ... scheduled to take place on Thursday, January 12, 2012 ... live audio webcast of Mr. Bentsur,s presentation will be ...
... (NASDAQ: VRML ) , a ... plan to streamline its organization and extend its cash runway. ... the company,s first complete year of commercialization progress and put ... in 2011.    With approximately $22.5 million in ...
... BLUE BELL, Pa., Jan. 4, 2012  Inovio Pharmaceuticals, Inc. ... cancers and infectious diseases, announced today that it has ... Research and Development to Chief Operating Officer. In his ... and business development for the company in addition to ...
Cached Biology Technology:Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference 2Vermillion Sharpens Focus and Streamlines Operations in 2012 2Vermillion Sharpens Focus and Streamlines Operations in 2012 3Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer 2Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer 3Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer 4Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer 5
(Date:7/2/2015)... , July 2, 2015 Fingerprint ... FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... The sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of approximately 2,200 ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... is not usually cause for concern, but it is often ... in girls, Turner syndrome is a genetic defect that short-circuits ... is not commonly detected until age 10 or older when ... lag before diagnosis of the condition can delay the start ...
... colonoscopies, including mice. University of Missouri researchers are ... to predict colon cancer caused by inflammation. A ... Diagnostic Laboratory (RADIL) could eventually lead to a ... working to develop novel therapeutics for colon cancer, ...
... Hospital of Philadelphia has announced the establishment of the ... A ceremony on Feb. 15 at the Hospital,s Ruth ... first holder of the chair, pediatric immunologist Jordan S. ... allow Dr. Orange to break new ground in his ...
Cached Biology News:New test shows promise for accurate diagnosis of Turner syndrome 2MU researchers believe discovery could lead to testing that displaces colonoscopies 2Modell Chair in Pediatric Immunology established 2
... Services include: ,ISH Protocol ... Conditions Analyses ,RNA and DNA ... Cells and Tissues ,Double Labeling ... Cells and Tissues ,RNA and ...
... the optimization of immunostaining. ... the primary antibody, selection and ... Alk. Phos., HRP, fluorescence, or ... evaluation by light or fluorescence ...
Request Info...
... Quality ISO 9001:2000 Certified USDA Research ... Validated, SOP's Training AALAS Certified ... All Procedures GLP Documentation Upon Request ... shopping point for all your custom immunology ...
Biology Products: